Latest news

Thumbnail

NICE backs non-surgical option for fibroids

Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the National Health Service for the first time, after cost regulators endorsed Gedeon Richter's once-daily pill Esmya as an option.

26th August 2016

Thumbnail

Stafford hospital shuts A&E to children

County Hospital in Stafford has suspended Accident and Emergency services for children, after senior clinicians advised that "the service is not currently clinically safe".

26th August 2016

Thumbnail

NHS deficit narrows in first quarter

The number of NHS providers booking a financial deficit dropped 20 percent during the first quarter of 2016/17, according to new figures released by NHS Improvement.

26th August 2016

Thumbnail

FDA rejects Amgen’s Parsabiv

US regulators have turned down Amgen's request to market Parsabiv for secondary hyperparathyroidism (sHPT).

25th August 2016

Thumbnail

GPs report drug shortages

The issue of drug shortages is coming to the fore again as a survey by GP Online finds that four out of five doctors are not able to give patients their first choice of treatment.

25th August 2016

Thumbnail

Servier’s Lonsurf backed for NHS use

Patients with advanced bowel cancer in England and Wales stand to gain routine access to a new treatment option after cost regulators backed NHS funding for Servier's Lonsurf.

25th August 2016

Thumbnail

Cell Medica links with UCL in research deal

Cell Medica has signed a research deal with University College London for access to its novel T cell receptor technology, in a bid to generate leading-edge modified TCR products for the treatment of cancer.

25th August 2016

Thumbnail

NICE expands NHS treatment options for CML, lung cancer

The National Institute for Health and Care Excellence has published two sets of guidelines increasing the treatment options for NHS patients with chronic myeloid leukaemia and non-small cell lung cancer.

25th August 2016

Thumbnail

AbbVie’s venetoclax joins UK’s early access scheme

AbbVie venetoclax has been accepted onto the UK's Early Access to Medicines Scheme (EAMS), having picked up a positive scientific opinion from the Medicines and Healthcare products Regulatory Agency for the treatment of chronic lymphocytic leukaemia.

24th August 2016

Thumbnail

NICE widens scope of Bayer’s Eylea

Cost regulators are now backing NHS use of Bayer's Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.

24th August 2016

Thumbnail

AZ sells antibiotics to Pfizer

AstraZeneca is selling to Pfizer rights to its late-stage small molecule antibiotics business in most markets globally outside the US, in a deal that could be worth near $1.6 billion.

24th August 2016

Thumbnail

DS Biopharma spins out Afimmune

Dublin, Ireland-based lipid science group DS Biopharma has launched a spin-out group focused solely on fibrotic conditions and pulmonary disorders.

23rd August 2016

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Head of Clinical Research

University of Oxford, Oxford Cent ...

£52,219 - £60,513 (with discretionary range to £66,109) per annum

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download